The short version of Purity assay fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Metandienone, also known as methandienone or methandrostenolone and sold under the brand name Dianabol (D-Bol) among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer prescribed. It is also used non-medically for physique- and performance-enhancing purposes. It is often taken by mouth. Side effects of metandienone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire, estrogenic effects like fluid retention and breast enlargement, and liver damage. The drug is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT), and has strong anabolic effects and moderate androgenic effects. It also has moderate estrogenic effects. Metandienone was originally developed in 1955 by CIBA and marketed in Germany and the United States. As the CIBA product Dianabol, metandienone quickly became the first widely used AAS among professional and amateur athletes, and remains the most common orally active AAS for non-medical use. It is currently a controlled substance in the United States and United Kingdom and remains popular among bodybuilders. Metandienone is readily available without a prescription in certain countries such as Mexico, and is also manufactured in some Asian countries.
Caffeine (stylised CAFFEINE; formerly Coffee Inn and Caffeine Roasters) is a coffeehouse chain headquartered in Vilnius, Lithuania. Founded in 2007, it is the largest branded coffee chain in the Baltic states, operating more than 100 cafés in Lithuania and additional stores in Latvia, Estonia, Norway and Denmark.
It has local production plants in Bologna and Florence in Italy along with other manufacturing sites in Germany, France, Switzerland, Spain, United Kingdom, U.S.A., India, Malaysia and China. More than 5,000 are employed in the company, 2,600 of those work abroad. Its annual turnover in 2016 was €1.310,55 million. Its employees number more than 5,000 (with about 2,600 outside of Italy) in 41 manufacturing sites in Italy, Germany, France, Switzerland, Spain, the UK, the US, India, Malaysia, China and Argentina. Its sales network covers more than 80 countries. The Group has around 6,000 employees, of which over 2,800 overseas, and has 45 production plants in Italy, Germany, France, Switzerland, Spain, United Kingdom, United States, India, Malaysia, China and Argentina. IMA has an extensive commercial network, which consists of 29 branches with sales and assistance services in Italy, France, Switzerland, United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and Eastern European countries and more than 50 agencies covering a total of about 80 countries. In addition, in 2019, it had a turnover of 1,595.5 million euros, of which about 90% outside Italy.
Sources: en.wikipedia.org
== Discovery of variants == Hemoglobin variants can be discovered through examination, routine laboratory testing, or evaluation of patients with severe anemia. In some countries, all newborns are tested for hemoglobinopathies, thalassemias, and HbS. Isoelectric focusing or high-performance liquid chromatography are used to identify structural abnormalities in hemoglobin.
=== RNAP sequencing === This method is based on use of RNA polymerase (RNAP), which is attached to a polystyrene bead. One end of DNA to be sequenced is attached to another bead, with both beads being placed in optical traps. RNAP motion during transcription brings the beads in closer and their relative distance changes, which can then be recorded at a single nucleotide resolution. The sequence is deduced based on the four readouts with lowered concentrations of each of the four nucleotide types, similarly to the Sanger method. A comparison is made between regions and sequence information is deduced by comparing the known sequence regions to the unknown sequence regions.
Plants absorb carbon, hydrogen, and oxygen from air and soil as carbon dioxide and water. Other nutrients are absorbed from soil (exceptions include some parasitic or carnivorous plants). Counting these, there are 17 important nutrients for plants: these are macronutrients; nitrogen (N), phosphorus (P), potassium (K), calcium (Ca), sulfur (S), magnesium (Mg), carbon (C), oxygen(O) and hydrogen (H), and the micronutrients; iron (Fe), boron (B), chlorine (Cl), manganese (Mn), zinc (Zn), copper (Cu), molybdenum (Mo) and nickel (Ni). In addition to carbon, hydrogen, and oxygen, nitrogen, phosphorus, and sulfur are also needed in relatively large quantities. Together, these six are the elemental macronutrients for all organisms. They are sourced from inorganic matter (for example, carbon dioxide, water, nitrates, phosphates, sulfates, and diatomic molecules of nitrogen and, especially, oxygen) and organic compounds such as acids, carbohydrates, lipids, proteins.
Sources: en.wikipedia.org
=== Gut microbiota === The effect of the low-FODMAP diet on the gut microbiota is not fully understood. It is thought that reduction of fermentable carbohydrates affects the composition and abundance of gut bacteria. FODMAPs are a main food source (prebiotic) for many gut bacteria. Deprived of this food source, there is less bacterial fermentation in the gut and less production of intestinal gas, which may also create conditions which favor certain species of bacteria and disfavor others. There is some evidence for negative effects of the low-FODMAP diet, such as reduction in the numbers of beneficial bacteria (e.g., Bifidobacteria). Such changes are comparable to dysbiosis. Other studies report no significant change in gut microbiota from the low-FODMAP diet. There is also some evidence for positive effects on the gut microbiota, such as improved microbial diversity and increased numbers of potentially beneficial bacterial species. The effect of the low-FODMAP diet on gut microbiota also seems to depend on the medical condition, with more profound changes in microbiota occurring in celiac disease or inflammatory bowel disease, but no significant microbiota changes occurring in IBS. Overall, the low-FODMAP diet may have a positive effect on the gut microbiota compared to normal diets. However, the evidence is mixed and there is significant study heterogeneity, probably because of variation in the methodology and length of the studies, and also differences in the studied populations such as genetics and baseline diet.
Collectivist and individualistic values also play a role in the manifestation of symptoms. Patients in China are more likely to display denial or minimization of symptoms since they are culturally encouraged to use conceal their symptoms to preserve group harmony. These cultural differences are further empathized in research on the Caribbean island of Curaçao which revealed a substantially lower overall incidence of anorexia nervosa than that observed in the United States and Western Europe. Specifically, no cases were identified among the majority Black population, while the minority mixed and white population showed incidence rates similar to those in Western countries. This disparity highlights potential cultural variations in the development and presentation of anorexia nervosa, particularly when comparing Black women in Curaçao to those exposed to Western cultural influences. Notably, although these cultural distinctions persist, modernization and globalization slowly homogenize these attitudes. Anorexia is increasingly tied to the pressures of a global culture that celebrates Western ideals of thinness. The spread of Western media, fashion, and lifestyle ideals across the globe has begun to shift perceptions and standards of beauty in diverse cultures, contributing to a rise in the incidence of anorexia in places they were once rare. Anorexia, once primarily associated with Western culture, seems more than ever to be linked to the cultures of modernity and globalization.
Boletus edulis (English: cep, penny bun, porcino) is a basidiomycete fungus, and the type species of the genus Boletus. It is prized as an edible mushroom. The fungus produces spore-bearing fruit bodies above ground in summer and autumn. The fruit body has a large brown cap which can reach 30 cm (12 in) in diameter and 3 kg (6 lb 10 oz) in weight. Like other boletes, it has tubes extending downward from the underside of the cap, rather than gills; spores escape at maturity through the tube openings (pores). The pore surface of the fruit body is whitish when young, aging to a greenish-yellow. The stout stipe (or stem) is white or yellowish, up to 25 cm (10 in) tall and 7 cm (3 in) thick, and partially covered with a raised network pattern (reticulations). The fungus grows in deciduous and coniferous forests and tree plantations, forming symbiotic ectomycorrhizal associations with living trees by enveloping the tree's underground roots with sheaths of fungal tissue. Widely distributed in the Northern Hemisphere across Eurasia and North America, it does not occur naturally in the Southern Hemisphere but has been introduced to it. Several closely related European mushrooms formerly thought to be varieties or forms of B. edulis have been shown using molecular phylogenetic analysis to be distinct species, while others previously classified as separate species are conspecific with B. edulis. The western North American species commonly known as the California king bolete (B. edulis var. grandedulis) is a large, darker-coloured variant first formally identified in 2007. B.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.